Odds ratio

Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021

Retrieved on: 
Friday, October 15, 2021
History, Private Securities Litigation Reform Act, Nasdaq, Metabolic disorder, Lists of diseases, UOX, Risk, Hyperoxaluria, Cancer, Urine, PKU, Metabolism, Diet, Engineering, Synthetic biology, Absorption, Therapy, Nephrocalcinosis, Disease, Medicine, Roux-en-Y anastomosis, Clinical trial, American Society of Nephrology, Biology, Intellectual property, Society, ASN, Poster, Collection, Odds ratio, Chronic kidney disease, Kidney, Inflammatory bowel disease, Short bowel syndrome, Pharmaceutical industry

CAMBRIDGE, Mass., Oct. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster presentations at the upcoming American Society for Nephrology (ASN) Kidney Week 2021, to be held virtually November 4 7th, 2021.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster presentations at the upcoming American Society for Nephrology (ASN) Kidney Week 2021, to be held virtually November 4 7th, 2021.
  • At this dose, the percent reduction from baseline UOx levels was -28.6% (90% CI: -42.4 to -11.6) compared to placebo in diet-induced hyperoxaluria.
  • Enteric Hyperoxaluria results in dangerously high levels of urinary oxalate, which causes progressive kidney damage, kidney stone formation, and nephrocalcinosis.
  • However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so.

New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis

Retrieved on: 
Monday, October 11, 2021
Science, Other Science, Biotechnology, Research, Oncology, Health, Medical Devices, Genetics, UIP, Confidence interval, Collection, Idiopathic pulmonary fibrosis, Vicki Belo, ILD, Odds ratio, HRCT, IPF, Physician, Diagnosis, Degenerative disease, Interstitial lung disease, Pulmonology, American College of Chest Physicians, Abstract, Tulane University School of Medicine, Decision-making, Patient, American College, Medical device, Medical imaging

(Nasdaq: VCYT) announced new data demonstrating that the Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic pulmonary fibrosis (IPF) by increasing diagnostic accuracy, physician confidence in diagnosis, and patient referral to appropriate therapy.

Key Points: 
  • (Nasdaq: VCYT) announced new data demonstrating that the Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic pulmonary fibrosis (IPF) by increasing diagnostic accuracy, physician confidence in diagnosis, and patient referral to appropriate therapy.
  • The Envisia Genomic Classifier is a highly accurate, clinically validated molecular test that detects a genomic pattern of usual interstitial pneumonia (UIP), a critical factor that can help physicians differentiate IPF from other ILDs.
  • Researchers led by Joseph Lasky, M.D., of Tulane University Medical School surveyed 103 practicing pulmonologists to determine the impact of the Envisia classifier on clinical decision-making in IPF.
  • Results show that the Envisia classifier significantly increases IPF diagnosis, physicians confidence in their diagnosis and recommendations for patients to initiate treatment.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA21

Retrieved on: 
Tuesday, October 5, 2021
Well, Mortality, NCDR, Man, CTO, VIVA, De novo, Macroinvertebrate Community Index, Diagnosis, PTA, Patient, Employment, Categorization, Randomized controlled trial, Medicare, Multimedia, LL, Boston Scientific, Atherectomy, Angiography, Wynn Las Vegas, White, Hypertension, Odds ratio, PVI, ISR, Calcification, TLR, Diabetes, Vascular disease, PAD, AOR, Freedom, Prevalence, DCB, Awareness, Ranger, Peripheral vascular examination, Center, Male, CI, Peripheral artery disease, Research, Association, Centers for Medicare & Medicaid Services, Safety, Ahr, Kaplan–Meier estimator, Index, Operational technology, DCI, Blood vessel, CLI, Amputation, Education, Medical imaging, Pharmaceutical industry, Medicine

Below are highlights of this morning's 4 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 4 late-breaking clinical trial presentations.
  • This presentation is the first report on the long-term safety and effectiveness follow-up outcomes of these independent prespecified cohorts.
  • The IN.PACT Global Study was a prospective, multicenter, single-arm study conducted at 64 international sites that enrolled 1,535 participants, including some with complex lesions.
  • Assessments through 5 years included freedom from clinically driven target lesion revascularization (CD-TLR), safety composite, and major adverse events.

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Retrieved on: 
Tuesday, October 5, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Mortality, PCR, Medical microbiology, Clinical trial, Assistant, Inflammatory Bowel Diseases, Orphan, Diagnosis, Recurrence, Infection, Therapy, United States Department of Health and Human Services, Doctor of Philosophy, Biomedical Advanced Research and Development Authority, Patient, Death, Population, Feces, BARDA, HHS, Development, MSU MFA Program in Science & Natural History Filmmaking, University, Disease, Odds ratio, Bacteria, Immune system, List of life sciences, Contract manufacturing organization, PRTC, LSE, CDI, Risk, Food allergy, Cell, Office of the Assistant Secretary for Preparedness and Response, Research, LBP, PureTech Health, Safety, Data analysis, Clostridioides difficile infection, Department, Pharmaceutical industry, Medical device, Antibiotics, VE303, Vedanta Biosciences, VE303, VEDANTA BIOSCIENCES

We believe these results are an important step forward for the prevention of C. difficile infection and the microbiome field at large.

Key Points: 
  • We believe these results are an important step forward for the prevention of C. difficile infection and the microbiome field at large.
  • Recurrent CDI causes approximately half a million infections each year in the United States, including up to 165,000 recurring infections and up to 45,000 deaths.
  • Based on the Phase 2 data, BARDA has exercised its first contract option for additional funding of $23.8 million pursuant to its existing 2020 contract with Vedanta.
  • Total committed funding under the BARDA award to date is $31.2 million, inclusive of this first contract option.

Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy

Retrieved on: 
Tuesday, August 10, 2021
Hypoxia, CNS, Patient, Pediatrics, Stanford University, Analgesic, IV, Central nervous system, Vomiting, Safety, Itch, Dizziness, Nausea, Odds ratio, DOI, Trevena, GLOBE, AES, Risk, Pharmaceutical industry

Hammer, M.D., Professor of Anesthesiology, Perioperative and Pain Medicine, and of Pediatrics at Stanford University (DOI: https://doi.org/10.1007/s40122-021-00299-0).

Key Points: 
  • Hammer, M.D., Professor of Anesthesiology, Perioperative and Pain Medicine, and of Pediatrics at Stanford University (DOI: https://doi.org/10.1007/s40122-021-00299-0).
  • IV opioids continue to play a key role in post-operative pain management in my practice.
  • These findings provide useful insight into the benefit-risk profile of OLINVYK and suggest that it can provide morphine-level pain relief with a lower risk of adverse events.
  • The findings from this analysis are compelling and suggest that OLINVYK may offer an improved benefit / risk profile for patients requiring IV opioids, said Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena.